Empagliflozin (SGLT2i)

DRUG3 trials

Sponsors

Kaiser Permanente, Hotel Dieu de France Hospital, Al-Azhar University

Conditions

CAD - Coronary Artery DiseaseCardiovascular DiseasesCoronary Artery Disease (CAD)DapagliflozinEmpagliflozinInflamationMyocardial InfarctionNo Reflow Phenomenon

Phase 2

Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI

Not yet recruitingNCT07898709

Al-Azhar UniversityCoronary Artery Disease (CAD), Dapagliflozin, Empagliflozin +6

Start: 2027-01-01End: 2027-08-01Target: 100Updated: 2026-10-27

Phase 4

Effect of Empagliflozin on Inflammation

RecruitingNCT07292909

Hotel Dieu de France HospitalCAD - Coronary Artery Disease, Inflamation, PCI +1

Start: 2025-09-01End: 2027-09-30Target: 100Updated: 2025-12-18

Unknown Phase

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

CompletedNCT05073692

Kaiser PermanenteCardiovascular Diseases, Type 2 Diabetes Mellitus

Start: 2021-07-01End: 2025-03-12Updated: 2025-11-21